You are on page 1of 2

68148 Federal Register / Vol. 67, No.

217 / Friday, November 8, 2002 / Notices

Conference Room 10 (6th floor), Name of Committee: National Cancer Dates: December 4–5, 2002.
Bethesda, Maryland 20892. Institute Special Emphasis Panel, Minority Open: December 4, 2002, 8:45 a.m. to 3:15
Contact Person: Ann Wagner, Ph.D., Institution/Cancer Centers Partnerships: p.m.
Division of Services and Intervention CA03–009, CA03–008, CA03–010. Agenda: Program reports and
Date: December 3–4, 2002. presentations; Business of the Board.
Research, National Institute of Mental Place: National Cancer Institute, 9000
Time: 7 p.m. to 5 p.m.
Health, NIH, 6001 Executive Boulevard, Agenda: To review and evaluate grant Rockville Pike, Building 31, C Wing, 6th
Room 7142, MSC 9633, Bethesda, applications. Floor, Conference Room 10, Bethesda, MD
Maryland 20892. Email: < Place: Bethesda Marriott, 5151 Pooks Hill 20892.
awagner@mail.nih.gov > Phone: 301– Road, Bethesda, MD 20814. Contact Person: Dr. Marvin R. Kalt,
443–4283. Contact Person: Ray Bramhall, Ph.D., Executive Secretary, National Cancer
Any member of the public interested Scientific Review Administrator, Special Institute, National Institutes of Health, 6116
in presenting oral comments to the Review, Referral and Resources Branch, Executive Boulevard, 8th Floor, Room 8001,
committee may notify the contact Division of Extramural Affairs, National Bethesda, MD 20892–8327, (301) 496–5147.
person listed on this notice at least 5 Cancer Institute, National Institutes of Name of Committee: National Cancer
Health, 6116 Executive Boulevard, Suite Advisory Board, Subcommittee on Planning
days in advance of the meeting.
8060, Rockville, MD 20892, (301) 594–1403. and Budget.
Interested individuals and Open: December 4, 2002, 11:05 a.m. to
representatives of organizations may (Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction; 11:55 a.m.
submit a letter of intent, a brief Agenda: To discuss activities related to the
93.393, Cancer Cause and Prevention
description of the organization Subcommittee on Planning and Budget.
Research; 93.394, Cancer Detection and
represented, and a short description of Diagnosis Research; 93.395, Cancer
Place: National Cancer Institute, 9000
the oral presentation. Presentations may Rockvill Pike, Building 31, C Wing, 6th
Treatment Research; 93.396, Cancer Biology
be limited to 5 minutes; both printed Floor, Conference Room 10, Bethesda, MD
Research; 93.397, Cancer Centers Support;
and electronic copies are requested for 20892.
93.398, Cancer Research Manpower; 93.399,
Contact Person: Ms. Cherie Nichols,
the record. In addition, any interested Cancer Control, National Institutes of Health,
Executive Secretary, Subcommittee on
person may file written comments with HHS)
Planning and Budget, National Cancer
the committee by forwarding his/her Dated: November 1, 2002. Institute, National Institutes of Health, 9000
statement to the contact person listed on LaVerne Y. Stringfield, Rockville Pike, Building 31, Room 11A03,
this notice. The statement should Director, Office of Federal Advisory Bethesda, MD 20892, (301) 496–5515.
include the name, address, telephone Committee Policy. Name of Committee: National Cancer
number and, when applicable, the [FR Doc. 02–28533 Filed 11–7–02; 8:45 am] Advisory Board.
business or professional affiliation of Closed: December 4, 2002, 3:15 p.m. to
BILLING CODE 4140–01–M
the interested person. Recess.
Information about the meeting is also Agenda: Review intramural program site
visit outcomes; Discussion of confidential
available on-line on the NIMH Home DEPARTMENT OF HEALTH SERVICES personnel issues.
Page at < http://www.nimh.nih.gov/iacc/ Place: National Cancer Institute, 9000
index.cfm >. National Institutes of Health Rockville Pike, Building 31, C Wing, 6th
Dated: October 31, 2002. Floor, Conference Room 10, Bethesda, MD
National Cancer Institute; Notice of 20892.
Ruth L. Kirschstein,
Meeting Contact Person: Dr. Marvin R. Kalt,
Deputy Director, National Institutes of Health. Executive Secretary, National Cancer
[FR Doc. 02–28539 Filed 11–7–02; 8:45 am] Pursuant to section 10(d) of the Institute, National Institutes of Health, 6116
BILLING CODE 4140–01–P
Federal Advisory Committee Act, as Executive Boulevard, 8th Floor, Room 8001,
amended (5 U.S.C. Appendix 2), notice Bethesda, MD 20892–8327, (301) 496–5147.
is hereby given of the meeting of the Name of Committee: National Cancer
DEPARTMENT OF HEALTH AND National Cancer Advisory Board. Advisory Board.
HUMAN SERVICES The meeting will be open to the Open: December 5, 2002, 8:30 a.m. to 12
public as indicated below, with p.m.
National Institutes of Health attendance limited to space available. Agenda: Program reports and
Individuals who plan to attend and presentations; Business of the Board.
National Cancer Institute; Notice of need special assistance, such as sign Place: National Cancer Institute, 9000
Closed Meeting language interpretation or other Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
Pursuant to section 10(d) of the reasonable accommodations, should 20892.
Federal Advisory Committee Act, as notify the Contact Person listed below Contact Person: Dr. Marvin R. Kalt,
amended (5 U.S.C. Appendix 2), notice in advance of the meeting. Executive Secretary, National Cancer
is hereby given of the following A portion of the meeting will be Institute, National Institutes of Health, 6116
meeting. closed to the public in accordance with Executive Boulevard, 8th Floor, Room 8001,
The meeting will be closed to the the provisions set forth in sections Bethesda, MD 20892–8327, (301) 496–5147.
public in accordance with the 552b(c)(4), and 552b(6), as amended. Any interested person may file
provisions set forth in sections The grant applications and the written comments with the committee
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., discussions could disclose confidential by forwarding the statement to the
as amended. The grant applications and trade secrets or commercial property Contact Person listed on this notice. The
the discussions could disclose such as patentable material, and statement should include the name,
confidential trade secrets or commercial personal information concerning address, telephone number and when
property such as patentable material, individuals associated with the grant applicable, the business or professional
and personal information concerning applications, the disclosure of which affiliation of the interested person.
individuals associated with the grant would constitute a clearly unwarranted In the interest of security, NIH has
applications, the disclosure of which invasion of personal privacy. instituted stringent procedures for
would constitute a clearly unwarranted Name of Committee: National Cancer entrance into the building by non-
invasion of personal privacy. Advisory Board. government employees. Persons without

VerDate 0ct<31>2002 16:24 Nov 07, 2002 Jkt 200001 PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 E:\FR\FM\08NON1.SGM 08NON1
Federal Register / Vol. 67, No. 217 / Friday, November 8, 2002 / Notices 68149

a government I.D. will need to show a Name of Committee: National Institute on Date: December 2, 2002.
photo I.D. and sign-in at the security Aging Special Emphasis Panel, Human Time: 1:30 p.m. to 3:30 p.m.
desk upon entering the building. Genetics. Agenda: To review and evaluate grant
Date: November 18–19, 2002. applications.
Information is also available on the Time: 7 p.m. to 5 p.m. Place: One Democracy Plaza, 6701
Institute’s/Center’s home page: Agenda: To review and evaluate grant Democracy Blvd., Suite 800, Bethesda, MD
deainfo.nci.nih.gov/advisory/ncab.htm, applications. 20892, (Telephone Conference Call).
where an agenda and any additional Place: The Iberville Suites—New Orleans, Contact Person: Tracy A Shahan, Ph.D.,
information for the meeting will be 910 Iberville Street, New Orleans, LA 70112. Scientific Review Administrator, National
Contact Person: Alicja L. Markowska, Institute of Arthritis and Musculoskeletal and
posted when available.
Ph.D., DSC, Scientific Review Office, Skin Diseases, 6701 Democracy Plaza,
(Catalogue of Federal Domestic Assistance Gateway Building/Suite 2C212, 7201 Bethesda, MD 20892, (301) 594–4952.
Program Nos. 93.392, Cancer Construction; Wisconsin Avenue, Bethesda, MD 20817.
(Catalogue of Federal Domestic Assistance
93.393, Cancer Cause and Prevention This notice is being published less than 15
Program Nos. 93.846, Arthritis,
Research; 93.394, Cancer Detection and days prior to the meeting due to the timing
Musculoskeletal and Skin Diseases Research,
Diagnosis Research; 93.395, Cancer limitations imposed by the review and
National Institutes of Health, HHS)
Treatment Research; 93.396, Cancer Biology funding cycle.
Dated: November 4, 2002.
Research; 93.397, Cancer Centers Support; Name of Committee: National Institute on
93.398, Cancer Research Manpower; 93.399, Aging Special Emphasis Panel, Intervention LaVerne Y. Stringfield,
Cancer Control, National Institutes of Health, Panel. Director, Office of Federal Advisory
HHS) Date: November 21, 2002. Committee Policy.
Dated: November 1, 2002. Time: 8 a.m. to 3:30 p.m. [FR Doc. 02–28528 Filed 11–7–02; 8:45 am]
Agenda: To review and evaluate grant
LaVerne Y. Stringfield, BILLING CODE 4140–01–M
applications.
Director, Office of Federal Advisory Place: Gateway Building, 7201 Wisconsin
Committee Policy. Avenue/Suite 2C212, Bethesda, MD 20814.
Contact Person: Arthur D. Schaerdel, DVM,
DEPARTMENT OF HEALTH AND
[FR Doc. 02–28534 Filed 11–7–02; 8:45 am]
The Bethesda Gateway Building, 7201 HUMAN SERVICES
BILLING CODE 4140–01–M
Wisconsin Avenue/Suite 2C212, Bethesda,
MD 20892, (301) 496–9666. National Institutes of Health
DEPARTMENT OF HEALTH AND (Catalogue of Federal Domestic Assistance National Institutes on Drug Abuse;
HUMAN SERVICES Program Nos. 93.866, Aging Research, Notice of Closed Meetings
National Institutes of Health, HHS)
National Institutes of Health Dated: November 4, 2002. Pursuant to section 10(d) of the
Anna Snouffer, Federal Advisory Committee Act, as
National Institute on Aging; Notice of Deputy Director, Office of Federal Advisory amended (5 U.S.C. Appendix 2), notice
Closed Meetings Committee Policy. is hereby given of the following
[FR Doc. 02–28527 Filed 11–7–02; 8:45 am] meetings.
Pursuant to section 10(d) of the The meetings will be closed to the
BILLING CODE 4140–01–M
Federal Advisory Committee Act, as public in accordance with the
amended (5 U.S.C. Appendix 2), notice provisions set forth in sections
is hereby given of the following DEPARTMENT OF HEALTH AND 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
meetings. HUMAN SERVICES as amended. The grant applications and
The meetings will be closed to the the discussions could disclose
public in accordance with the National Institutes of Health confidential trade secrets or commercial
provisions set forth in sections property such as patentable material,
552b(c)(4) and 552(c)(6), Title 5 U.S.C., National Institute of Arthritis and and personal information concerning
as amended. The grant applications and Musculoskeletal and Skin Diseases; individuals associated with the grant
the discussions could disclose Notice of Closed Meeting applications, the disclosure of which
confidential trade secrets or commercial Pursuant to section 10(d) of the would constitute a clearly unwarranted
property such as patentable material, Federal Advisory Committee Act, as invasion of personal privacy.
and personal information concerning amended (5 U.S.C. Appendix 2), notice Name of Committee: National Institute on
individuals associated with the grant is hereby given of the following Drug Abuse Special Emphasis Panel, Program
applications, the disclosure of which meeting. Project.
would constitute a clearly unwarranted The meeting will be closed to the Date: November 20, 2002.
Time: 10 am to 2 pm.
invasion of personal privacy. public in accordance with the Agenda: To review and evaluate grant
Name of Committee: National Institute on provisions set forth in sections applications.
Aging Special Emphasis Panel, T32’s. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Place: 6001 Executive Boulevard, Suite
Date: November 12–14, 2002. as amended. The grant applications and 3158, Bethesda, MD 20892–9547 (Telephone
Time: 7 p.m. to 5 p.m. the discussions could disclose Conference Call).
Agenda: To review and evaluate grant confidential trade secrets or commercial Contact Person: Khursheed Asghar, Ph.D.,
applications. property such as patentable material, Chief, Basic Sciences Review Branch, Office
Place: Chevy Chase Holiday Inn, 5520 and personal information concerning of Extramural Affairs, National Institute on
Wisconsin Ave., Chevy Chase, MD 20815. individuals associated with the grant Drug Abuse, National Institutes of Health,
Contact Person: Jeffrey M. Chernak, Ph.D., DHHS, 6001 Executive Boulevard, Room
applications, the disclosure of which 3158, MSC 9547, Bethesda, MD 20892–9547,
The Bethesda Gateway Building, 7201
would constitute a clearly unwarranted (301) 443–2620.
Wisconsin Avenue/Suite 2C212, Bethesda,
MD 20892, (301) 496–9666. invasion of personal privacy. Name of Committee: National Institute on
This notice is being published less than 15 Name of Committee: National Institute of Drug Abuse Special Emphasis Panel,
days prior to the meeting due to the timing Arthritis and Musculoskeletal and Skin Minority Institutions’ Drug Abuse Research
limitations imposed by the review and Diseases Special Emphasis Panel, Gordon Development Program (MIDARP).
funding cycle. Conference Review. Date: December 5, 2002.

VerDate 0ct<31>2002 17:16 Nov 07, 2002 Jkt 200001 PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 E:\FR\FM\08NON1.SGM 08NON1